Exploring the Options for Optimal Neuromuscular Blockade and Reversal

Start Course Now

Class A Credits: 1

Pharmacology Credits: 0.5

Format: Video

Run time: 20 mins

Course Launch Date: 10/30/20

Course Expires: 10/29/21

Neuromuscular blocking agents (NMBAs) enable anesthesia providers to temporarily paralyze patients during anesthesia. The introduction of NMBAs in anesthesia meant that optimal surgical conditions could be achieved with lower doses of volatile or intravenous anesthetics, improving hemodynamic stability. Although a powerful anesthetic tool, neuromuscular blockade (NMB) has the potential for significant adverse outcomes. Hence, providers need to be well-versed with the latest options for neuromuscular blockade and reversal. In this educational activity, expert clinicians review conventional agents used in NMB reversal, discuss new and emerging NMB reversal agents, as well as discuss the importance of multidisciplinary care in patients undergoing NMB reversal.

This course was created by Vindico Medical Education and sponsored by an educational grant from Merck & Co., Inc.

The American Association of Nurse Anesthetists is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

AANA is an approved provider by the California Board of Registered Nursing, CEP #10862.

Post-Test Attempt Notice
A minimum passing score of 80% is required to pass this course. You have TWO opportunities to achieve a passing score. If you fail to achieve a passing score of 80%, you will not receive CE credit for this course.

Content Disclaimer:

The views, information, or opinions expressed within the videos and audio are solely those of the individuals involved and do not necessarily represent those of the American Association of Nurse Anesthetists.

Course content has been prepared by the presenter/developer, and each viewer agrees that the presenter/developer is solely responsible for the content and the accuracy thereof. The viewer agrees that the American Association of Nurse Anesthetists has no responsibility or liability for the accuracy or completeness of the content.

  • Review the benefits and limitations of currently available reversal agents.
  • Apply the clinical data on current/emerging options for the reversal of neuromuscular blocking agents and their potential for improved patient recovery.
  • Implement multidisciplinary approaches to managing surgical patients who require deep neuromuscular blockade.

Anthony L. Kovac, MD

Kasumi Arakawa Professor of Anesthesiology

University of Kansas Medical Center

Kansas City, KS

J. Ross Renew, MD, FASA, FASE

Assistant Professor of Anesthesiology

Mayo Clinic

Jacksonville, FL

Matthew L. Kirkland, MD, FACS

Clinical Associate Professor of Surgery

Director Bariatric Surgery Program

Pennsylvania Hospital

Philadelphia, PA